This company has been marked as potentially delisted and may not be actively trading. AzurRx BioPharma (AZRX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock AZRX vs. IBIO, AEON, OBSV, AEZS, NRBO, ORGS, CPHI, MTNB, SPRB, and NBYShould you be buying AzurRx BioPharma stock or one of its competitors? The main competitors of AzurRx BioPharma include iBio (IBIO), AEON Biopharma (AEON), ObsEva (OBSV), Aeterna Zentaris (AEZS), NeuroBo Pharmaceuticals (NRBO), Orgenesis (ORGS), China Pharma (CPHI), Matinas Biopharma (MTNB), Spruce Biosciences (SPRB), and NovaBay Pharmaceuticals (NBY). These companies are all part of the "medical" sector. AzurRx BioPharma vs. Its Competitors iBio AEON Biopharma ObsEva Aeterna Zentaris NeuroBo Pharmaceuticals Orgenesis China Pharma Matinas Biopharma Spruce Biosciences NovaBay Pharmaceuticals iBio (NYSE:IBIO) and AzurRx BioPharma (NASDAQ:AZRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment. Which has higher valuation & earnings, IBIO or AZRX? iBio has higher revenue and earnings than AzurRx BioPharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioiBio$375K32.58-$24.91MN/AN/AAzurRx BioPharmaN/AN/A-$32.67M-$11.50-0.04 Do institutionals and insiders hold more shares of IBIO or AZRX? 7.9% of iBio shares are owned by institutional investors. Comparatively, 6.3% of AzurRx BioPharma shares are owned by institutional investors. 0.6% of iBio shares are owned by insiders. Comparatively, 7.3% of AzurRx BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer IBIO or AZRX? In the previous week, iBio's average media sentiment score of 0.00 equaled AzurRx BioPharma'saverage media sentiment score. Company Overall Sentiment iBio Neutral AzurRx BioPharma Neutral Which has more risk and volatility, IBIO or AZRX? iBio has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, AzurRx BioPharma has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Is IBIO or AZRX more profitable? iBio's return on equity of -73.15% beat AzurRx BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets iBioN/A -73.15% -45.51% AzurRx BioPharma N/A -482.96%-258.47% Do analysts rate IBIO or AZRX? iBio presently has a consensus target price of $5.00, suggesting a potential upside of 576.04%. Given iBio's stronger consensus rating and higher possible upside, research analysts plainly believe iBio is more favorable than AzurRx BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iBio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00AzurRx BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryiBio beats AzurRx BioPharma on 8 of the 10 factors compared between the two stocks. Get AzurRx BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AZRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AZRX vs. The Competition Export to ExcelMetricAzurRx BioPharmaPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.59M$815.42M$5.72B$9.48BDividend YieldN/A4.84%4.59%3.98%P/E Ratio-0.051.3827.9219.95Price / SalesN/A24.93441.30102.64Price / CashN/A19.5636.5558.97Price / Book-0.656.818.635.90Net Income-$32.67M-$4.28M$3.24B$258.42M AzurRx BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AZRXAzurRx BioPharmaN/A$0.49-0.6%N/A-52.0%$4.59MN/A-0.0512Gap UpIBIOiBio1.4709 of 5 stars$0.72-5.2%$4.30+493.2%-66.9%$11.98M$375K0.00100AEONAEON Biopharma2.6961 of 5 stars$0.80-4.3%$360.00+44,956.3%-99.5%$9.03MN/A4.445Gap DownOBSVObsEvaN/AN/AN/AN/A$7.94MN/A-0.1150AEZSAeterna ZentarisN/A$3.62+2.5%N/A-22.8%$6.49M$2.37M-0.2420Gap DownNRBONeuroBo PharmaceuticalsN/A$0.71-1.1%N/A-83.9%$6.12MN/A0.0010High Trading VolumeORGSOrgenesis1.8339 of 5 stars$1.19+0.8%N/AN/A$5.71M$662K0.00150Gap UpCPHIChina Pharma0.6005 of 5 stars$1.70-10.1%N/A-93.2%$5.55M$4.30M0.00250Gap DownHigh Trading VolumeMTNBMatinas BiopharmaN/A$0.99-1.0%N/AN/A$5.04MN/A-0.2030Gap DownSPRBSpruce Biosciences1.9907 of 5 stars$0.10-6.3%$1.75+1,711.6%-76.6%$4.08M$4.91M-0.1020News CoverageStock SplitGap DownNBYNovaBay Pharmaceuticals1.6687 of 5 stars$0.67-2.9%$0.85+26.9%-69.2%$3.90M$9.78M-0.0130 Related Companies and Tools Related Companies IBIO Alternatives AEON Alternatives OBSV Alternatives AEZS Alternatives NRBO Alternatives ORGS Alternatives CPHI Alternatives MTNB Alternatives SPRB Alternatives NBY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AZRX) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AzurRx BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AzurRx BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
